Escalation pathways for complex anticoagulation introduced after patient death A patient died from prosthetic aortic valve thrombosis with sub-therapeutic anticoagulation, after clinicians were unable to keep her international normalised ratio within a therapeutic range.…
Selective NSAIDs reduce risk of GI bleeding, study suggests Researchers observed that when COX-2-selective non-steroidal anti-inflammatory drugs were used with direct-acting oral anticoagulants for nonvalvular atrial fibrillation, the risk of gastrointestinal bleeding decreased by more than one-third.…
Health news round-up: public health, cardiovascular risk and take-up of new medicines on the NHS Our weekly summary of important developments in pharmacy and health news you may have missed.…
Apixaban linked to lower risk of recurrent blood clots compared with warfarin Compared with warfarin, people in both frail and non-frail cohorts taking apixaban experienced an average of 12.1 fewer days of home time loss, a study found.…
Apixaban safer than rivaroxaban for thrombosis treatment, study finds Researchers found that patients who took anticoagulant apixaban for the treatment of venous thrombosis experienced less “clinically relevant bleeding”, compared with those who received rivaroxaban.…
Prescribing dilemma: balancing risk and benefit when prescribing anticoagulation in an older patient with falls risk This real-world dilemma examines the decision-making process when considering anticoagulation in older patients.…
Coroner highlights lack of head injury warnings for anticoagulant A patient prescribed apixaban, who died following a fall, was unaware of the risks that the anticoagulant presented in the event of head trauma.…
Case-based learning: women’s health and anticoagulation How considerations for anticoagulation in the presence of heavy menstrual bleeding can change over a woman’s life course.…
Standard-dose DOACs not necessarily better than reduced dose, study results suggest Researchers found that “non-inferiority” of a reduced dose of direct oral anticoagulants could not be determined when compared with a standard dose, with “reliably low rates” of recurrent venous thromboembolism.…
New class of anticoagulant found to ‘overwhelmingly’ reduce bleeding events in patients with atrial fibrillation Experts say the results of this “exciting” two-year study of abelacimab “add to the growing evidence that inhibition of factor XI may preferentially impact thrombosis over haemostasis”.…
